Orally administered β-glucans enhance anti-tumor effects of monoclonal antibodies

Cancer Immunology, Immunotherapy

Volumn 51, Issue 10, 2002, Pages 557-564

  Cheung, Nai Kong V ^a   Modak, Shakeel ^a   Vickers, Andrew ^a   Knuckles, Benny ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WESTERN REGIONAL RESEARCH CENTER   (United States)

Author keywords

(1 3),(1 4) D glucan; ADCC; CMC; CR3

Indexed keywords

BETA 1,3 GLUCAN; BETA 1,4 GLUCAN; BETA 1,6 GLUCAN; BETA GLUCAN; CD20 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GANGLIOSIDE GD2; GANGLIOSIDE GD3; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3F8; MONOCLONAL ANTIBODY 3G6; MONOCLONAL ANTIBODY 8H9; MONOCLONAL ANTIBODY R24; ONCOPROTEIN; RITUXIMAB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SCREENING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOTHERAPY; LINKAGE ANALYSIS; LYMPHOMA; MELANOMA; MOUSE; NEUROBLASTOMA; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR IMMUNITY; TUMOR LOCALIZATION; TUMOR VOLUME; XENOGRAFT;

EID: 0036035607     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-002-0321-3     Document Type: Article

References (59)

1. Alberts DS, Martinez ME, Roe DJ, Guillen-Rodriguez JM, Marshall JR, van Leeuwen JB, Reid ME, Ritenbaugh C, Vargas PA, Bhattacharyya AB, Earnest DL, Sampliner RE (2000) Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians' Network. N Engl J Med 342:1156
2. Bergman I, Basse PH, Barmada MA, Griffn JA, Cheung NKV (2000) Comparison of in vitro antibody-targeted cytoxicity using mouse, rat and human effectors. Cancer Immunol Immunother 49:259
3. Bjorge L, Hakulinen J, Wahlstrom T, Matre R, Meri S (1997) Complement-regulatory proteins on ovarian malignancies. Int J Cancer 70:14
4. Bohn JA, BeMiller JN (1995) (1-3)-β-D-Glucans as biological response modifiers: A review of structure-functional activity relationships. Carbohydr Polymers 28:3
5. Brasoveanu LI, Altomonte M, Gloghini A, Fonsatti E, Coral S, Gasparollo A, Montagner R, Cattarossi I, Simonelli C, Cattelan A, Attadia V, Carbone A, Maio M (1995) Expression of protectib (CD59) in human melanoma and its functional role in cell- and complement-cytotoxicity. Int J Cancer 61:548
6. Cain JA, Newman SL, Ross GD (1987) Role of complement receptor type three and serum opsonins in the neutrophil response to yeast. Complement Inflammation 4:75
7. Cheung N, Modak S (2002) Oral (1-3),(1-4)-beta-glucan syngergizes with anti-ganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma. Clin Cancer Res 8:1217
8. Cheung NK, Saarinen U, Neely J, Landmeier B, Donovan D, Coccia P (1985) Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res 45:2642
9. Ciucanu I, Kerek F (1984) A simple and rapid method for the permethylation of carbohydrates. Carbohydrate Res 131:209
10. Czop JK, Austen KF (1985) Properties of glycans that activate the human alternative complement pathway and interact with the human monocyte beta-glucan receptor. J Immunol 135:3388
11. Di Renzo L, Yefenof E, Klein E (1991) The function of human NK cells is enhanced by beta-glucan, a ligand of CR3 (CD11b/CD18). Eur J Clin Nutr 21:1755
12. Diller IC, Mankowski ZT, Fisher ME (1963) The effect of yeast polysaccharides on mouse tumors. Cancer Res 23:201
13. Ebina T, Fujimiya Y (1998) Antitumor effect of a peptide-glucan preparation extracted from Agaricus blazei in a double-grafted tumor system in mice. Biotherapy 11:259
14. Fujimoto S, Furue H, Kimura T, Kondo T, Orita K, Taguchi T, Yoshida K, Ogawa N (1991) Clinical outcome of postoperative adjuvant immunochemotherapy with sizofiran for patients with resectable gastric cancer: A randomised controlled study. Eur J Cancer 27:1114
15. Hara T, Kojiama A, Fukuda H, Masaoka T, Fukumori Y, Matsumoto M, Seya T (1992) Levels of complement regulator protein, CD35(CR1), CD46(MCP) and CD55(DAF) in human haematological malignancies. Br J Haemotol 82:368
16. + T-cell response in gut-associated lymphoid tissue (GALT) of specific-pathogen-free mice. Int J Cancer 70:362
17. Houghton AN, Mintzer D, Cordon-Cardo C, Welt S, Fliegel B, Vadhans S, Carswell E, Melamed MR, Oettgen HF, Old LJ (1985) Mouse monoclonal antibody-detecting GD3 ganglioside: A phase I trial in patients with malignant melanoma. Proc Natl Acad Sci USA 82:1242
18. Iino Y, Yokoe T, Maemura M, Horiguchi J, Takei H, Ohwada S, Morishita Y (1995) Immunochemotherapies versus chemotherapy as adjuvant treatment after curative resection of operable breast cancer. Anticancer Res 15:2907
19. Ikuzawa M, Matsunaga K, Nishiyama S, Nakajima S, Kobayashi Y, Andoh T, Kobayashi A, Ohhara M, Wada T, Yoshikumi C (1988) Fate and distribution of an antitumor protein-bound polysaccharide PSK (Krestin). Int J Immunopharmacol 10:415
20. Irie K, Irie RF, Morton DL (1974) Evidence for in vivo reaction of antibody and complement to surface antigens of human cancer cells. Science 186:454
21. Juhl H, Helmig F, Baltzer K, Kalthoff H, Henne-Bruns D, Kremer B (1997) Frequent expression of complement resistance factors CD46,CD55, and CD55 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17-1A. J Surg Oncol 64:222
22. Jurianz K, Maslak S, Garcia-Schuler H, Fishelson Z, Kirschfink M (1999) Neutralization of complement regulatory proteins augments lysis of breast carcinoma cells targeted with rhumAb anti-HER2. Immunopharmacology 42:209
23. Jurianz K, Ziegler S, Garcia-Schuler H, Kraus S, Bohana-Kashtan O, Fishelson Z, Kirschfink M (1999) Complement resistance of tumor cells: Basal and induced mechanisms. Mol Immunol 36:929
24. Klein E, DiRenzo L, Yefenof E (1990) Contribution of C3, CD11b/CD18 to cytolysis by human NK cells. Mol Immunol 27:1343
25. Knuckles BE, Yokohama WH, Chiu MM (1997) Molecular characterization of barley β-glucans by size-exclusion chromatography with multiple-angle laser-light scattering and other detectors. Cereal Chem 74:599
26. Koretz K, Bruderlein S, Henne C, Moller P (1993) Expression of CD59, a complement regulator protein and a second ligand of the CD2 molecule, and CD46 in normal and neoplastic colorectal epithelium. Br J Cancer 68:926
27. Marquart HV, Gronbaek K, Christensen BE, Svehag S-E, Lesli RGQ (1995) Complement activation by malignant B-cells from patients with chronic lymphocytic leukemia. Clin Exp Immunol 102:575
28. Masui H, Moroyama T, Mendelsohn J (1986) Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes. Cancer Res 46:5592
29. McCoy JP, Hofheinz DE, Ng AB, Nordqvist S, Haines HG (1979) Tumor-bound immunoglobulin in human gynecologic cancers. J Natl Cancer Inst 63:279
30. Mitomi T, Tsuchiya S, Iijima N, Aso K, Suzuki K, Nishiyama K, Amano T, Takahashi T, Murayama N, Oka H (1992) Randomized, controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. The cooperative study group of surgical adjuvant immunochemotherapy for cancer of colon and rectum (Kanagawa). Dis Colon Rectum 35:123
31. Modak S, Kramer K, Humayun G, Guo HF, Cheung NKV (2001) Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors. Cancer Res 61:4048
32. Nakazato H, Koike A, Saji S, Ogawa N, Sakamoto J (1994) Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Lancet 343:1122
33. Nanba H, Kubo K (1997) Effect of maitake D-fraction on cancer prevention. Ann NY Acad Sci 833:204
34. Nanba H, Kuroda H (1987) Antitumor mechanisms of orally administered shiitake fruit bodies. Chem Pharm Bull (Tokyo) 35:2459
35. Niimoto M, Hattori T, Tamada R, Sugimachi K, Inokuchi K, Ogawa N (1988) Postoperative adjuvant immunochemotherapy with mitomycin C, futraful, and PSK for gastric cancer. An analysis of data on 579 patients followed for five years. Jpn J Surg 18:681
36. Ogoshi K, Satou H, Isono K, Mitomi T, Endoh M, Sugita M (1995) Immunotherapy for esophageal cancer. A randomized trial in combination with radiotherapy and radiochemotherapy. Cooperative study group for esophageal cancer in Japan. Am J Clin Oncol 18:216
37. Ohno N, Miura NN, Nakajima M, Yadomae T (2000) Anti-tumor 1,3-β-glucan from cultured fruit body of Sparassis crispa. Biol Pharm Bull 23:866
38. Ohno N, Suzuki I, Oikawa S, Sato K, Miyazaki T, Yadomae T (1984) Antitumor activity and structural characterization of glucans extracted from cultured fruit bodies of Grifola frondosa (Tokyo). Chem Pharm Bull 32:1142
39. Ohno R, Yamada K, Masaoka T, Ohshima T, Amaki I, Hirota Y, Horikoshi N, Horiuchi A, Imai K, Kimura I (1984) A randomized trial of chemoimmunotherapy of acute nonlymphocytic leukemia in adults using a protein-bound polysaccharide preparation. Cancer Immunol Immunother 18:149
40. Okamura K, Suzuki M, Chihara T, Fujiwara A, Fukada T, Goto S, Ichinohe K, Jimi S, Kasamatsu T, Kawai N (1989) Clinical evaluation of sizofiran conbined with irradiation in patients with cervical cancer. A randomized controlled study; a five-year survival rate. Biotherapy 1:103
41. Ross GD, Cain JA, Lachmann PJ (1985) Membrane complement receptor type three (CR3) has lectin-like properties analogous to bovine conglutinin and functions as a receptor for zymosan and rabbit erythrocytes as well as a receptor for iC3b. J Immunol 134:3307
42. Ross GD, Cain JA, Myones BL, Newman SL, Lachmann PJ (1987) Specificity of membrane complement receptor type three (CR3) for beta-glucans. Complement Inflammation 4:61
43. Roubroeks JP, Skjak-Braek G, Ryan L, Christensen BE (2000) Molecular weight dependency on the production of the TNF stimulated by fractions of rye (1->3), (1->4)-beta-D-glucan. Scand J Immunol 52: 584
44. Seegal BC, Hsu KC, Lattimer JK, Habif DV, Tannenbaum M (1976) Immunoglobulins, complement and foreign antigens in human tumor cells. Int Arch Allergy Immunol 52:205
45. 125I-tyraminyl cellobiose. Immunopharmacology 21:149
46. Sobanov Y, Bernreiter A, Derdak S, Mechtcheriakova D, Schweighofer B, Duchler M, Kalthoff F, Hofer E (2001) A novel cluster of lectin-like receptor genes expressed in monocytic, dendritic and endothelial cells maps close to the NK receptor genes in the human NK gene complex. Eur J Immunol 31:3493
47. Suda M, Ohno N, Adachi Y, Yadomae T (1994) Relationship between the tissue distribution and antitumor activity of highly branched (1->3)-beta-D-glucan, SSG. Biol Pharm Bull 17:131
48. Suzuki I, Sakurai T, Hashimoto H, Oikawa S, Masuda A, Ohsawa M, Yadomae T (1991) Inhibition of experimental pulmonary metastasis of Lewis lung carcinoma by orally administered beta-glucan in mice. Chem Pharm Bull (Tokyo) 39:1606
49. Sveinbjornsson B, Rushfeldt C, Seljelid R, Smedsrod B (1998) Inhibition of establishment and growth of mouse liver metastases after treatment with interferon gamma and beta-1,3-D-glucan. Hepatology 27(5):1241
50. Thornton BP, Vetvicka V, Pitman M, Goldman RC, Ross GD (1996) Analysis of the sugar specificity and molecular location of the β-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18). J Immunol 156:1235
51. Toi M, Hattori T, Akagi M, Inokuchi K, Orita K, Sugimachi K, Dohi K, Nomura Y, Monden Y, Hamada Y (1992) Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer. Five-year results from the Nishi-Nippon group of the adjuvant chemoendocrine therapy for breast cancer organization. Cancer 70:2475
52. Torisu M, Hayashi Y, Ishimitsu T, Fujimura T, Iwasaki K, Katano M, Yamato H, Kimura Y, Takesue M, Kondo M (1990) Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancer. Cancer Immunol Immunother 31:261
53. Vetvicka V, Thornton BP, Ross GD (1996) Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells. J Clin Invest 98:50
54. Vetvicka V, Thornton BP, Wieman TJ, Ross GD (1997) Targeting of natural killer cells to mammary carcinoma via naturally occurring tumor cell-bound iC3b and beta-glucan-primed CR3 (CD11b/CD18). J Immunol 159: 599
55. Willment JA, Gordon S, Brown GD (2001) Characterization of the human beta-glucan receptor and its alternatively spliced isoforms. J Biol Chem 276:43818
56. Wyatt P (1993) Light scattering and the absolute characterization of macromolecules. Anal Chim Acta 272:1
57. Xia Y, Vetvicka V, Yan J, Hanikyrova M, Mayadas T, Ross GD (1999) The beta-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells. J Immunol 162:2281
58. Yan J, Vetvicka V, Xia Y, Coxon A, Carroll MC, Mayadas TN, Ross GD (1999). β-Glucan: A "specific" biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement recoptor type 3 (CD11b/CD18). J Immunol 163:3045
59. Yan J, Vetvicka V, Xia Y, Hanikyrova M, Mayadas TN, Ross GD (2000) Critical role of Kupffer cell CR3 (CD11b/CD18) in the clearance of IgM-opsonized erythrocytes or soluble beta-glucan. Immunopharmacology 46:39